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ABSTRACT: Overcoming the natural defensive barrier
functions of the eye remains one of the greatest challenges
of ocular drug delivery. Cornea is a chemical and mechanical
barrier preventing the passage of any foreign bodies including
drugs into the eye, but the factors limiting penetration of
permeants and nanoparticulate drug delivery systems through
the cornea are still not fully understood. In this study, we
investigate these barrier properties of the cornea using
thiolated and PEGylated (750 and 5000 Da) nanoparticles,
sodium ﬂuorescein, and two linear polymers (dextran and
polyethylene glycol). Experiments used intact bovine cornea in
addition to bovine cornea de-epithelialized or tissues pre-
treated with cyclodextrin. It was shown that corneal epithelium is the major barrier for permeation; pretreatment of the cornea
with β-cyclodextrin provides higher permeation of low molecular weight compounds, such as sodium ﬂuorescein, but does not
enhance penetration of nanoparticles and larger molecules. Studying penetration of thiolated and PEGylated (750 and 5000 Da)
nanoparticles into the de-epithelialized ocular tissue revealed that interactions between corneal surface and thiol groups of
nanoparticles were more signiﬁcant determinants of penetration than particle size (for the sizes used here). PEGylation with
polyethylene glycol of a higher molecular weight (5000 Da) allows penetration of nanoparticles into the stroma, which proceeds
gradually, after an initial 1 h lag phase.
KEYWORDS: cornea, silica nanoparticles, PEGylated nanoparticles, permeation, β-cyclodextrin, ﬂuorescence
■ INTRODUCTION
The eye is a complex organ with various tissues and cells, many
of which are incapable of regeneration, including the corneal
endothelium and the photoreceptor layer of the retina.
Irreparable damage to these tissues, potentially resulting in
blindness, can be caused by inﬂammation or ocular infection
with microbial pathogens.1 According to the World Health
Organization, there are 285 million people living with serious
vision disorders worldwide. Among them, 39 million people are
blind. This number may rise to 76 million by 2020 without
eﬀective interventions. However, 75% of severe disorders
including blindness can be treated and prevented.2 Therefore,
targeted drug delivery to the eye has become an area of
signiﬁcant research and interest for pharmaceutical scientists.
It is important for the eye to regulate the environment
around ocular tissues. There are tight cellular barriers in the
anterior and posterior parts of the eye that restrict the uptake of
ﬂuids and prevent penetration of foreign bodies. As a defensive
function, ocular barriers also protect the eye from active
pharmaceutical ingredients. The design of targeted ocular drug
delivery systems to overcome these barriers remains one of the
greatest challenges in pharmaceutical science.3 In treating major
diseases of the posterior eye segment, such as age related
macular degeneration (the most common cause of blindness),
retinal degeneration, diabetic retinopathy, and glaucoma,
intravitreal drug administration is widely used.4−7 This invasive
method is the most direct approach to deliver drugs to the
posterior eye segment providing therapeutic tissue drug levels;
however, it has serious potential side eﬀects of retinal
detachment, hemorrhage, endophthalmitis and cataract. Addi-
tionally, the repeated injections that are usually required are not
well tolerated by patients.8 Therefore, this approach is
considered to be potentially dangerous, and other less invasive
methods are still needed.4
The most commonly used dosage form in treating ocular
diseases is locally applied eye drops.3,9,5b Topical administration
of drugs is beneﬁcial for delivery to the anterior (cornea,
conjunctiva, sclera, anterior chamber) as well as posterior
(vitreous humor, retina, choroid) segments of the eye.
However, due to lachrymal drainage, systemic absorption, and
biological barriers (principally the corneal epithelium), only a
Received: May 5, 2014
Revised: July 10, 2014
Accepted: August 22, 2014
Published: August 28, 2014
Article
pubs.acs.org/molecularpharmaceutics
© 2014 American Chemical Society 3556 dx.doi.org/10.1021/mp500332m | Mol. Pharmaceutics 2014, 11, 3556−3564
Terms of Use CC-BY
small fraction of the applied dose (less than 5%) reaches the
intraocular tissues.3,10 In particular, it was reported to be
extremely diﬃcult to deliver drug to posterior segments of the
eye, due to anatomy and physiology of the eye.5c Following
drug administration to the ocular surface, there are two main
pathways by which the drug can enter the eye: either the
corneal or conjunctival route.3 The latter is of minor relevance
for the majority of drugs and is mostly the route of absorption
for biopharmaceuticals (proteins or peptides) since the
conjunctiva is permeable to hydrophilic and large molecules.3
However, most clinically used drugs are relatively small and
lipophilic, hence, the corneal route usually dominates in ocular
topical drug delivery.9
It is well-known that the cornea is a signiﬁcant mechanical
and chemical barrier to drug delivery. It is an optically
transparent tissue that protects the inner parts of the eye.3,10
The diameter of the cornea is around 11.7 mm, and the
thickness is 0.5−0.7 mm; the cornea is thicker in the center
than in the limbus.10 The cornea consists of 5 layers:
epithelium, Bowman’s membrane, stroma, Descemet’s mem-
brane, and endothelium.11 A cross section of bovine cornea
with the epithelium, Bowman’s membrane, and stroma
highlighted can be seen in Figure S1 (Supporting Information).
Usually, the corneal epithelium is the main barrier restricting
drug absorption into the eye.10,12 Stroma and endothelium, on
the other hand, provide very little resistance to transcorneal
permeation; as essentially aqueous layers, they inhibit
permeation of only highly lipophilic compounds.13,14 The
epithelium thickness is 50−90 μm, which is in a proportional
relationship to stroma and endothelium as 1:10:0.1.10
In attempts to overcome the chemical and mechanical
barriers, nanoparticles have been used to extend the residence
time of formulations on the ocular mucosa and to increase
corneal penetration of the drug. Nanoparticle-based drug
delivery systems have shown promising results in ophthalmic
research over the past 10 years.15 Positively charged nano-
particles, as drug carriers in iontophoresis studies, demon-
strated higher penetration into anterior and posterior ocular
structures compared to their negatively charged counterpart,
ensuring prolonged therapeutic activity for more than 12 h post
treatment.16 Nanoparticles with hydrolyzable dye were also
shown to have high penetration rates overcoming both
mechanical (epithelium tight junctions) and chemical (lip-
ophilic epithelium and hydrophilic stroma) barriers of the
cornea.17 Chitosan in the form of nanoparticles was more
eﬀective in interacting with ocular surfaces compared to
solutions of linear polymer.18 Ammonium palmitoyl glycol
chitosan-based nanoparticles facilitated the absorption of the
anti-inﬂammatory drug prednisolone across the cornea,
providing high levels of drug loading and signiﬁcantly
enhancing drug bioavailability.19 Another study using chitosan
nanoparticles reported increased delivery of cyclosporin A to
the corneal and conjunctival surfaces, providing long-term drug
levels, but did not enhance the penetration of the drug into the
inner part of the eye. The electrostatic interaction between
positively charged chitosan and negatively charged cells of the
cornea was suggested to be more responsible for the prolonged
residence of cyclosporin A on the epithelial surface than
mucoadhesive properties of chitosan.18 However, Calvo et al.
demonstrated the opposite: the speciﬁc nature of chitosan was
responsible for enhancing the ocular penetration of indome-
thacin rather than the positive surface charge of poly-ε-
caprolactone (PECL) nanoparticles provided by chitosan and
poly-L-lysine coatings.20
Although there are a number of studies that have recently
reported enhanced ocular drug delivery by using nanoparticles,
the main factors limiting the passage of nanoparticulate drug
carriers through the corneal barriers are still not fully
understood: whether it is the size of nanoparticles or the
presence of speciﬁc interactions between them and ocular
surface. Therefore, in the current work, we studied the barrier
functions of the cornea using two types of silica nanoparticles of
diﬀerent sizes with diﬀerent surface chemistry: thiolated and
PEGylated (750 and 5000 Da), ﬂuorescently labeled with 5-
(iodoacetamido)ﬂuorescein (5-IAF) and contrasted with large
and small (ﬂuorescein−dextran and sodium ﬂuorescein)
molecular penetration. Permeation studies were conducted in
vitro, using bovine corneas, on intact, pretreated with β-
cyclodextrin, and scraped epithelium tissues.
■ EXPERIMENTAL SECTION
Materials. (3-Mercaptopropyl)trimethoxysilane (MPTS,
95%), methoxypolyethylene glycol maleimide with average
molecular weights 750 and 5000 Da (PEG 750 and PEG 5000,
respectively), 5-(iodoacetamido)ﬂuorescein, sodium ﬂuorescein
(376 Da), ﬂuorescein isothiocyanate dextran (4000 Da), O-[2-
(3-mercaptopropionylamino)ethyl]-O′-methylpolyethylene gly-
col (5000 Da) (PEG 5000), 5,5′-dithiobis(2-nitrobenzoic acid)
(DTNB), and L-cysteine hydrochloride were purchased from
Sigma-Aldrich, Inc. (U.K.) and used as received. Dimethyl
sulfoxide (DMSO) and sodium hydroxide (NaOH) were
purchased from Fisher Scientiﬁc Ltd. (U.K.) and were
laboratory grade reagents. OCT Embedding Matrix was also
supplied by the same manufacturer. Additionally, β-cyclodextrin
was purchased from TCI Europe N.V., Belgium, and used as
received.
Synthesis of Thiolated Silica Nanoparticles. Thiolated
silica nanoparticles were synthesized according to a protocol
adapted from Mun et al.23 Brieﬂy, 0.75 or 0.38 mL of MPTS
was mixed with 20 mL of DMSO and 0.5 mL of 0.5 mol/L
NaOH aqueous solution (diﬀerent volumes of MPTS resulted
in the formation nanoparticles of groups A and B, respectively).
The reaction was conducted under air bubbling and allowed to
proceed for 24 h with permanent stirring at room temperature.
Puriﬁcation of nanoparticles was by dialysis against deionized
water (5 L, 8 changes of water) with dialysis tubing of 12−
14000 Da molecular weight cutoﬀ (Medicell International Ltd.,
U.K.).
Ellman’s Assay. Thiol-group content was determined by
Ellman’s assay.21 Brieﬂy, 0.2−0.3 mg of freeze-dried nano-
particles was hydrated in 500 μL of phosphate buﬀer solution
(0.5 mol/L, pH 8) and allowed to react with 500 μL of 5,5′-
dithiobis(2-nitrobenzoic acid) (DTNB) (0.3 mg/mL) for 2 h.
The absorbance was then measured at 420 nm (Epoch
Microplate Spectrophotometer, BioTek Instruments, USA).
The calibration curve was elaborated with cysteine hydro-
chloride solutions over the concentration range of 25−175
μmol/L.
Synthesis of Fluorescently Labeled Thiolated Silica
Nanoparticles. Synthesized silica nanoparticles were labeled
with 5-(iodoacetamido)ﬂuorescein (5-IAF) similarly to the
protocol described by Irmukhametova et al.21 Brieﬂy, 3 and 0.3
mg of 5-IAF were added to 18 and 20 mL of aqueous
dispersion of nanoparticles of 44 (group A) and 21 nm (group
B), respectively. The amount of 5-IAF added was calculated
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with regard to molar ratios such that 5 μmol of ﬂuorophore was
added to 50 μmol of SH groups of thiolated nanoparticles. The
reaction mixture was stirred for 16 h at room temperature
protected from light. Then, ﬂuorescently labeled nanoparticles
were puriﬁed by dialysis against deionized water in the dark
according to the previously described protocol.21
PEGylation of Fluorescently Labeled Silica Nano-
particles. 5 mL of ﬂuorescently labeled nanoparticles (5
mg/mL) was mixed with 100 mg of methoxypolyethylene
glycol maleimide of two molecular weights (750 and 5000
Da).The reaction mixture was stirred during 16 h at room
temperature protected from light. PEGylated nanoparticles
were puriﬁed by dialysis in the dark as above.
Synthesis of Fluorescently Labeled PEG (5000 Da).
100 mg of methoxypolyethylene glycol maleimide 5000 Da was
dissolved in 5 mL of deionized water, then 2 mg of 5-
(iodoacetamido)ﬂuorescein was added, and the reaction
mixture was allowed to proceed for 16 h under permanent
stirring at room temperature. Fluorescently labeled PEG 5000
(5-IAF-PEG) was puriﬁed by dialysis against deionized water (5
L, 8 changes of water in total) using cellulose membranes with
100−500 Da molecular weight cutoﬀ (Spectrum Laboratories
Inc., CA, USA).
Preparation of Solutions. 0.5 and 2 mg of sodium
ﬂuorescein (376 Da) and ﬂuorescein isothiocyanate dextran
(FITC-dextran, 4000 Da), respectively, were each dissolved in
10 mL of deionized water and were left for 5 h under
permanent stirring at room temperature. 30 mL of β-
cyclodextrin solution was prepared at 20 mg/mL by dissolving
in deionized water at 60 °C under permanent stirring followed
by cooling of the solution to physiological temperature before
use.
The “Whole Eye” Method for Studying the Perme-
ability of Silica Nanoparticles. Permeation studies were
conducted using the “whole eye” method to avoid the risk of
corneal swelling observed when employing Franz diﬀusion cells
with fully dissected tissues.29 Bovine eyes used in these
experiments were obtained from P.C. Turner Abattoir
(Hampshire, U.K.). Freshly extracted eyes, with the cornea
covered by the lid, were transported to the laboratory in a cold
box and stored in the fridge at 4 °C overnight prior to use,
shown in our earlier work to have no adverse eﬀects on tissue
barrier properties.29 For permeation studies, each eye was
placed into a glass beaker with the Franz cell donor
compartment on top, secured with a cling ﬁlm (Figure S2,
Supporting Information). The central cornea of the eye was
then exposed to 1 mL of one of the solutions: thiolated,
PEGylated (750 Da), or PEGylated (5000 Da) nanoparticle
dispersion (5 mg/mL) for 2 h. For experiments with pretreated
and removed corneal epithelium, some pretreatment proce-
dures were carried out prior to nanoparticle exposure. In the
former case, the eye was exposed to 1 mL of β-cyclodextrin
aqueous solution (20 mg/mL) for 1 h, after which this solution
was withdrawn with a syringe. In the latter case, the epithelium
layer was carefully scraped oﬀ the cornea with a metal spatula.
These procedures were followed by exposing the eye to one of
the nanoparticle solutions.
All experiments were conducted in triplicate, in a water bath
at 37 °C. After 2 h treatment, the cornea was extracted from the
eye, and the area exposed to the sample solutions was excised
using a sharp blade. Three diﬀerent segments of each cornea
were mounted in OCT and kept on dry ice. Cross sectioning (7
μm thick sections) of each corneal segment was performed on a
cryostat (Bright, model OTF)/microtome (Bright, model
5040) and ﬁxed in groups of six on 75 mm × 25 mm glass
slides followed by application of 50−75 μL of 4′,6-diamidino-2-
phenylindole (DAPI; 1.5 μg/mL) to stain the cell nuclei.
Fluorescence Microscopy. Cross sections of cornea were
examined using ﬂuorescence microscopy (Zeiss Imager A1 with
AxioCam MRm Zeiss camera); each image was taken using
DAPI (blue, maximum λemission = 461 nm) and Fluor (green,
maximum λemission = 519 nm) ﬁlters and then overlaid as a
composite image.
Dynamic Light Scattering. The size of ﬂuorescently
labeled silica nanoparticles was determined using dynamic light
scattering with a Nano-ZS series (Malvern Instruments, U.K.)
at 25 °C. Each sample was analyzed three times, and the
average hydrodynamic diameters are presented as a mean value
± standard deviation.
Fluorescence Spectroscopy. Fluorescence spectra were
recorded for ﬂuorescently labeled thiolated and PEGylated
nanoparticles using a FP-6200 spectroﬂuorometer (Jasco, U.K.)
over the wavelength range 505−700 nm (λex = 492 nm).
■ RESULTS AND DISCUSSION
Synthesis and Characterization of Silica Nanopar-
ticles. Synthesis of thiolated silica nanoparticles in DMSO was
previously reported by Irmukhametova et al.21,22 resulting in 55
± 4 nm particles. Recently, we also reported a slightly modiﬁed
synthetic protocol,23 which was used in the present study. The
reaction mixture containing 0.2 mol/L MPTS was bubbled with
atmospheric air providing additional cross-linking via S−S
bridges and resulting in the formation of nanoparticles of 45 ±
1 nm (subsequently referred to as group A). The concentration
of MPTS in the reaction mixture is one factor controlling the
size of nanoparticles; halving the concentration of MPTS for
the synthesis (0.1 mol/L) formed smaller nanoparticles, 21 ± 1
nm (subsequently referred to as group B).
Silica nanoparticles were ﬂuorescently labeled with 5-
(iodoacetamido)ﬂuorescein (5-IAFL) by reaction with 5-IAFL
(Figure S3, Supporting Information). The ﬂuorophore was
added into the reaction mixture in a ratio of 5:50 μmol with
regard to the number of SH groups of silica nanoparticles; thus
there remained thiol groups available for further PEGylation of
some of the ﬂuorescently labeled samples.
Samples of ﬂuorescently labeled thiolated silica nanoparticles
of each size (44 and 21 nm) were PEGylated with
methoxypolyethylene glycol maleimide of two molecular
weights (750 and 5000 Da). Two groups of nanoparticles
were produced:
1. A: consisting of 44 nm thiolated and PEGylated (750
and 5000 Da) nanoparticles
2. B: consisting of 21 nm thiolated and PEGylated (750 and
5000 Da) nanoparticles
The DLS distributions demonstrate the greater sizes of
PEGylated nanoparticles due to the presence of a PEG corona
on their surfaces (Figure 1 and Table 1). Comparison of the
sizes of thiolated and PEGylated nanoparticles was conducted
using Anova software (Tukey’s multiple comparison test)
revealing signiﬁcant diﬀerences between each sample within the
groups A (p < 0.001) and B (p < 0.05 and p < 0.001). The
increase in size was 9 and 24 nm in group A and 6 and 22 nm in
group B for PEG750 and PEG5000 nanoparticles, respectively,
compared to thiolated particles.
Molecular Pharmaceutics Article
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Due to the screening eﬀect of PEG shells, reduced 5-IAFL
ﬂuorescence intensities were observed for PEGylated nano-
particles. PEG of a larger molecular weight provided the lowest
intensity since screening with PEG5000 Da is greater than with
PEG750 Da (Figure S4, Supporting Information). These results
are in good agreement with our previously reported
observations for PEGylation of silica nanoparticles labeled
with Alexa Fluor maleimide.23
The general characteristics of ﬂuorescently labeled silica
nanoparticles are summarized in Table 1.
As seen from this table, the polydispersity index (PDI) values
for both groups A and B decrease on PEGylation. This can be
explained by the formation of PEG-based polymer shells
around the silica cores that prevent the nanoparticles from
aggregating via disulﬁde bridges. The parent thiolated silica
nanoparticles do show some tendency to aggregate due to
disulﬁde bridge formation, which results in higher PDI values.
Comparative Permeability Studies on Intact and
Pretreated with β-Cyclodextrin Corneal Epithelium.
Franz diﬀusion cells have been widely employed for in vitro
transcorneal permeation studies for many years.24−28 However,
corneal swelling was observed when using Franz cells, and
dissected ocular tissues undergo structural changes with time.
To overcome these drawbacks, the “whole eye” method was
developed.29
Sodium ﬂuorescein salt was initially used as a model agent,
since corneal permeation of this low molecular weight
compound was previously reported.30,31 After 2 h of exposure
of bovine eye to sodium ﬂuorescein, ﬂuorescence micrographs
show penetration of this dye through the epithelium into the
stroma. However, this ﬂuorescent probe is not evenly
distributed throughout all parts of the cornea: in some areas
sodium ﬂuorescein is observed in the stroma within 2 h of
dosing whereas other areas show no permeation through the
epithelium after 2 h exposure (shown in Figure 2).
Although the corneal epithelium is permeable to low
molecular weight compounds, its tight junctions restrict the
passage of larger molecules. The maximum molecular weight
that can permeate through the cornea was reported to be 500
Da,32 but an earlier study by Huang et al.14 showed that the
cornea is only impermeable to molecules larger than 5000 Da.
Our experiments indicate that sodium ﬂuorescein, a water-
soluble compound with a molecular weight of 376 Da,
penetrates into and permeates through the corneal epithelial
membrane. Thus, to explore the molecular weight selectivity of
this membrane, larger compounds, namely, FITC-dextran
(4000 Da) and 5-IAF-PEG (5000 Da), were used to study
molecular weight eﬀects on corneal permeation. FITC-dextran
was selected as a material close to the molecular weight of PEG
(5000 Da) that we used in functionalizing silica nanoparticles.
As higher molecular weight compounds, neither FITC-dextran
nor 5-IAF-PEG 5000 permeated through the corneal
epithelium, but instead formed a layer on its surface which is
seen as a green band in Figure 3.
Cyclodextrins are well-known to enhance penetration into
biological barriers, such as skin and cornea, and so improve the
bioavailability of topically applied drugs.33,34 They are water-
soluble cyclic oligosaccharides with a lipophilic central cavity
and a hydrophilic outer surface, containing six, seven, or eight
glucopyranose units. Aqueous cyclodextrin solutions were
shown to disrupt the corneal epithelium integrity by extracting
cholesterol and other lipids from ocular membranes, making
the corneal barrier less resistant to permeation of hydrophilic
and hydrophobic compounds.29 Additionally, the same study
reported β-cyclodextrin to be the most eﬀective (among other
Figure 1. Size distribution of thiolated and PEGylated nanoparticles of
groups A and B, ﬂuorescently labeled with 5-IAFL.
Table 1. Characteristics of Thiolated and PEGylated Nanoparticles of Groups A and B, Fluorescently Labeled with 5-IAFL
group sample name diameter, nm PDI nanoparticle concn, mg/mL max emission, nm max intensity
A thiolated 45 ± 1 0.332 5 515 505
PEGylated (750 Da) 54 ± 1 0.194 5 517 443
PEGylated (5000 Da) 69 ± 2 0.145 7 516 415
B thiolated 21 ± 1 0.263 4 515 336
PEGylated (750 Da) 27 ± 1 0.254 4 515 146
PEGylated (5000 Da) 43 ± 3 0.231 6 515 132
Figure 2. Exemplar ﬂuorescence micrographs of cross section of
bovine cornea (corneal epithelium is shown in blue) with sodium
ﬂuorescein (green). Scale bar: 500 μm. Images a, b, and c were taken
from diﬀerent regions of the same eye.
Figure 3. Exemplar ﬂuorescence micrographs of cross section of
bovine cornea (blue) with FITC-dextran 4000 Da (a) and 5-IAF-PEG
5000 Da (b) (green). Each experiment was performed in triplicate
using diﬀerent eyes. Size bar: 100 μm.
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types of cyclodextrins) in enhancing permeability of riboﬂavin
through fresh and cryopreserved corneas.29
Applying β-cyclodextrin solution onto the bovine eye for 1 h,
before removal and the dosing with ﬂuorescent marker
solutions, enhanced the penetration of sodium salt ﬂuorescein.
The stroma images were analyzed with ImageJ software for the
cornea treated with β-cyclodextrin and an untreated one.
Compared to dye distribution for nontreated cornea, β-
cyclodextrin pretreatment produced more homogeneous
distribution of sodium ﬂuorescein in the stroma, observed
across the whole exposed area of the cornea (Figure 4).
Although there are studies reporting the delivery of dextrans
up to 4 and 70 kDa into the cornea, enhanced with borneol and
anodal iontophoresis,30,35 applying β-cyclodextrin prior to
exposing the cornea to either FITC-dextran 4000 Da or PEG
5000 did not demonstrate any permeation enhancement of
these compounds (Figure 5). There is evident disruption of the
epithelium layer caused by the treatment with β-cyclodextrin in
agreement with our previous report;29 however, FITC-dextran
4000 Da and PEG 5000 Da were only observed on the corneal
surface, suggesting that the integrity of the cornea was not
disrupted suﬃciently for the larger molecules to penetrate.
Nanomaterials have been employed in various in vitro
corneal permeation experiments, including the use of
carboxymethyl tamarind kernel polysaccharide nanoparticles,36
thiolated pectin nanoparticles,37 and droplet nanosized α-
tocopherol emulsion formulations.38a These studies reported
enhanced permeation of tropicamide, timolol maleate, and
indometacin from the nanosystems using dissected cornea. The
“whole eye” method provides experimental in vitro conditions
that are closer to the in vivo situation because this model avoids
potential artifacts when using removed ocular tissue in Franz
diﬀusion cells. However, it should be borne in mind that
periocular and choroid clearance mechanisms are absent when
in vitro models are used.38b To investigate the permeability of
bovine cornea to nanoparticle-type formulations, three types of
silica nanoparticles of group A (thiolated and PEGylated with
PEG of two molecular weights, 750 and 5000 Da), were applied
onto the bovine eye. Fluorescence microscopy images suggest
that none of these nanoparticles penetrated the cornea, even for
the epithelium treated with β-cyclodextrin (Figure 6).
The ocular surface is one of the mucosal tissues in the human
body that are coated by a mucus layer of glycoproteins
(mucins) with cysteine-containing domains.39 The mucus layer,
secreted by conjunctival goblet cells, is part of a three layered
structure of the precorneal tear ﬁlm. This ﬁlm plays an
important role in forming a continuous ﬂuid layer over the
cornea, keeping it moist, protecting it from bacterial infections,
providing lubrication for the movement of the eyelids, and
removing foreign bodies from its surface. According to the
“three layers theory” of the precorneal tear ﬁlm, the mucus
layer was believed to be the innermost one, beneath the
superﬁcial oily and middle aqueous layers.11 However, others
report that the mucus is present throughout the tear ﬁlm.40
Bernkop-Schnurch et al.41 reported that thiolated (thiol
bearing side chains) polymers are able to covalently bond to
mucins via disulﬁde bridges, which markedly improves their
mucoadhesive properties. In addition, poly(vinylpyrrolidone)/
poly(acrylic acid)−cysteine thiomer nanoparticles were dem-
onstrated to enhance the delivery of insulin by prolonging its
residence time on the stomach mucosa due to the covalent
bond formation between cysteine domains of mucin and
PAA.42 Similarly to thiomers, thiolated silica nanoparticles were
reported to have excellent mucoadhesive properties assessed by
evaluating their retention time on bovine ocular surfaces.21
However, their PEGylated counterpart demonstrated signiﬁ-
cantly lower mucoadhesion. In agreement with Irmukhametova
et al.,21 our thiolated silica nanoparticles (SH-group content =
Figure 4. Penetration of sodium ﬂuorescein into the bovine cornea
pretreated with β-cyclodextrin. Images a, b, c were taken from
experiments with the same eye. Scale bar: 500 μm; ﬂuorescence
density (ﬂuorescence intensity/area) of sodium ﬂuorescein in the
stroma pretreated with β-cyclodextrin and untreated cornea, analyzed
with ImageJ software (10 images were analyzed of each sample) (d).
Figure 5. Exemplar ﬂuorescence micrographs of cross section of
bovine cornea, pretreated with β-cyclodextrin, exposed to FITC-
dextran 4000 Da (a) and 5-IAFL-PEG 5000 Da (b). Each experiment
was performed in triplicate using diﬀerent eyes. Size bar: 100 μm.
Figure 6. Exemplar ﬂuorescence micrographs of cross section of
bovine cornea with intact (a) and pretreated with β-cyclodextrin (b)
epithelium, exposed to silica nanoparticles of group A ranging from 45
to 69 nm diameters. Size bar: 500 μm (a), 200 μm (b). Each
experiment was performed in triplicate with diﬀerent eyes.
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249 ± 30 μmol/g) were observed on the corneal surface
indicating no permeation, due to disulﬁde bond formation
between the thiol groups of nanoparticles and cysteine groups
of mucins. These interactions may be a limiting factor in
penetration of thiolated nanoparticles into bovine cornea. Upon
PEGylation, a number of SH groups of thiolated nanoparticles
is screened by PEG, and this eﬀect is more signiﬁcant with
larger PEG. For example, the SH-group content for nano-
particles PEGylated with 750 Da PEG was 95 ± 6 μmol/g,
whereas for 5000 Da PEG it was 78 ± 5 μmol/g. Therefore, the
interactions between nanoparticles and the mucus layer of the
cornea are considerably reduced by PEGylation. However,
neither PEGylated 750 nor 5000 Da nanoparticles can
penetrate into the cornea, which suggests that the nanoparticle
size (greater for PEGylated nanoparticles, Table 1) is a further
factor limiting penetration.
To test the barrier function of bovine cornea to smaller
nanoparticles, thiolated and PEGylated nanoparticles of group
B were applied onto the eye surface with intact and pretreated
with β-cyclodextrin epithelium. Again, no penetration for any of
these smaller nanoparticles was observed, which suggests that
the tight junctions of the corneal epithelium prevent
penetration of any particles into the eye surface, even as
small as 21 ± 1 nm (Figure S5, Supporting Information). For
thiolated nanoparticles, the presence of SH groups forms an
additional barrier due to the attractive mucoadhesive
interactions with mucosal surface of the eye. Applying β-
cyclodextrin improved penetration of sodium ﬂuorescein by
partially disrupting epithelium tight junctions, but this
disruption of corneal integrity is not suﬃcient to allow
nanoparticle penetration.
Ocular Permeability Studies of Silica Nanoparticles
with Removed Epithelium. Stroma is known to be more
permeable to larger molecules than epithelium.11 To investigate
if stroma also acts as a barrier to nanoparticle penetration, silica
nanoparticles of groups A and B were applied onto the bovine
eye, following the same experimental protocol, but with the
epithelium layer removed prior to nanoparticle exposure. The
epithelium layer is removed as a gel, and the visual diﬀerence
between the intact bovine eye and the one with removed
epithelium conﬁrmed removal of this layer (Figure S6,
Supporting Information).
The physical removal of epithelium is currently used as an
initial stage of a procedure to treat some ocular conditions such
as keratoconus. This de-epithelialization allows enhanced
permeability of riboﬂavin, which is used in corneal cross-
linking.43 Stroma has a relatively open “gel-like” structure
allowing the diﬀusion of compounds with a molecular weight
below 500 000 Da.11 Corneal stroma mainly consists of
regularly arranged collagen ﬁbers and keratocytes, which are
responsible for repair and maintenance. Before 1982, it was
believed that the only collagen type present in corneal stroma is
type I, however it was demonstrated for the ﬁrst time by
Newsome and co-workers44 and later conﬁrmed by another
group45,46 that corneal stroma consists of diﬀerent types of
collagen including type III, which contains cysteine and
cysteine domains. In addition, Saika et al.47 reported that
collagen type III is produced in higher proportions than
collagen type I in the early stages of the healing process.
The interactions between cysteine domains of the corneal
stroma and sulfhydryl groups of thiolated silica nanoparticles
are believed to be a limiting barrier in nanoparticle permeation
rather than their size. To test this hypothesis, thiolated and
PEGylated silica nanoparticles of groups A and B were applied
onto the bovine eyes with removed epithelium according to the
above-described protocol (Figure 7).
It is seen that thiolated nanoparticles, due to the interactions
of SH groups with cysteine domains of the stroma, do not
penetrate into the eye, even with the epithelial layer removed,
and this is not aﬀected by nanoparticle size (Figure 7a,b).
These particles tend to adhere to the stromal surface, which is
in agreement with an earlier study reporting the mucoadhesive
properties of thiolated silica nanoparticles.21 Upon PEGylation
with PEG maleimide of 750 Da, some thiol groups are screened
by the polymer, but a signiﬁcant number of SH groups ([SH] =
95 ± 6 μmol/g) remain available for binding to cysteine-rich
domains of the stroma. Therefore, there is still no penetration
observed for PEGylated (750 Da) nanoparticles. However,
when PEG maleimide of a higher molecular weight (5000 Da)
was used, nanoparticles of both types (groups A and B, 69 ± 2
nm and 43 ± 3 nm, respectively) penetrated into the ocular
stroma. This is likely to be due to the larger number of thiol
groups substituted with PEG of a greater molecular weight
([SH] = 78 ± 5 μmol/g), compared to PEG 750, and also the
large and bulky PEG chains surrounding the remaining surface
SH groups, eﬀectively screening the thiol groups and
preventing them from interacting with cysteine domains of
the ocular stroma. The enhanced permeation of PEGylated
nanoparticles is in agreement with the ﬁndings reported by
Hanes et al., who have reported that PEGylated nanoparticles
do not interact with biological tissues, such as human mucus,
due to strong hydrophilicity and neutral charge provided by
PEG coating, which helps the diﬀusion of nanoparticles.48,49
PEGylation was also demonstrated to improve cytoplasmic
transport of nanoparticles50 and penetration into vitreous gel
studied using fresh bovine vitreous.51
Our materials were designed to enable particle size eﬀects
and surface chemistry eﬀects to be interrogated as determinants
of nanoparticle penetration and permeation. Thus, two diﬀerent
nanoparticles (thiolated of group A and PEGylated 5000 Da
nanoparticles of group B) are a similar size (45 ± 1 nm and 43
± 3 nm, respectively; t test, p = 0.335), but with diﬀerent
surface coverage ([SH] = 249 ± 30 and 41 ± 3 μmol/g,
Figure 7. Exemplar ﬂuorescence micrographs of cross sections of de-
epithelialized bovine cornea, exposed to silica nanoparticles of groups
A (a) and B (b) for 2 h. Each experiment was performed in triplicate
using diﬀerent eyes. Size bar: 500 μm (a), 200 μm (b).
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respectively). While the sizes are consistent, the diﬀerences in
surface chemistries and consequent mucoadhesion provide
diﬀerent levels of penetration, illustrating that the interactions
between the ocular surface and nanoparticles is the limiting
factor for ocular penetration and not the particle size of these
particular materials when the epithelium is removed.
To explore the time course of nanoparticle uptake, the
bovine eyes with removed epithelium were exposed to thiolated
and PEGylated nanoparticles of group A for 0.5 and 1 h (Figure
8).
No diﬀerence in penetration of thiolated and PEGylated 750
Da nanoparticles (group A) upon 0.5 and 1 h of exposure time
was observed, compared to 2 h, conﬁrming no penetration of
those nanoparticles through the ocular stroma for the reasons
described above. However, the distribution of PEGylated 5000
Da nanoparticles varies with exposure time: there was no
penetration observed after 0.5 h exposure, whereas some
nanoparticles are clearly present in the stroma after 1 h, but not
to the extent of penetration after 2 h of exposure. To evaluate
the degree of penetration of PEGylated 5000 Da nanoparticles
at diﬀerent times, the ﬂuorescence micrographs were analyzed
and the ﬂuorescence intensity in the stroma was assessed using
ImageJ software (Figure 9).
■ CONCLUSIONS
In the present work, the barrier functions of the cornea were
studied using small and large molecular weight ﬂuorescent
probes and thiolated and PEGylated (750 and 5000 Da)
nanoparticles. The “whole eye” method was employed to avoid
corneal swelling and structural changes it might undergo when
using isolated cornea in Franz diﬀusion cells. In agreement with
previous publications, it was shown that the epithelium is the
major limiting barrier to penetration and permeation. β-
Cyclodextrin disrupts integrity of the epithelium providing
higher permeation of low molecular weight compounds, such as
sodium ﬂuorescein, but not enhancing the permeability of
larger molecules and nanoparticles. To investigate the limiting
factors for nanoparticle permeation (size or possible
interactions with corneal surface), further experiments were
conducted with removed epithelium. Nanoparticles of two
groups were applied. Comparison of two types of nanoparticles
of the same size and diﬀerent number of SH groups on the
surface revealed that the binding of nanoparticles to collagen is
a more important factor that prevents their penetration through
the de-epithelialized ocular tissues, and this phenomenon does
not depend on the particle size. PEGylation with PEG of a
higher molecular weight (5000 Da) provides screening of the
majority of thiol groups on the surface of nanoparticles,
allowing the passage of PEGylated nanoparticles into the
stroma. However, thiolated and PEGylated (750 Da) nano-
particles, possessing adhesive properties, stay on the ocular
surface. The permeation of PEGylated (5000 Da) nanoparticles
into the stroma proceeds gradually, starting after 1 h, reaching
over 15 au of ﬂuorescence intensity in the stroma at 2 h of the
exposure time.
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